- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| GELTEQ Aktie jetzt für 0€ handeln | |||||
| 17.12. | Gelteq Limited: Gelteq Receives FDA Approval of its Suitability Petition for New Animal Drug | 1 | GlobeNewswire (USA) | ||
| 02.12. | Gelteq Limited: Gelteq Announces Largest U.S. Customer Increases Initial Order by 50% to Meet Growing Market Demand | 2 | GlobeNewswire (USA) | ||
| 26.11. | Gelteq Limited: Gelteq Announces 400,000 Units Enter into Production in November 2024 | 1 | GlobeNewswire (USA) | ||
| 15.11. | Gelteq Ltd - 20-F, Annual and transition report of foreign private issuers | - | SEC Filings | ||
| 12.11. | Gelteq Limited: Gelteq Expands Operations in United States with Appointment of Adam Bendell as President of U.S. Operations to Scale Domestic Business | 1 | GlobeNewswire (USA) | ||
| 30.10. | Gelteq Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 30.10. | Gelteq Closes $5.2M IPO | 1 | Investing.com | ||
| 30.10. | Gelteq Limited Closes US$5.2 Million Initial Public Offering | 87 | GlobeNewswire (Europe) | NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Gelteq Limited ("Gelteq" or the "Company"), a global biotechnology company that specializes in the formulation, development, and manufacturing of ingestible... ► Artikel lesen | |
| 29.10. | Biotech company Gelteq prices IPO at $4 per share | 16 | Seeking Alpha | ||
| 29.10. | Gelteq Limited Prices US$5.2 Million Initial Public Offering | 352 | GlobeNewswire (Europe) | NEW YORK, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Gelteq Limited ("Gelteq" or the "Company"), a global biotechnology company that specializes in the formulation, development, and manufacturing of ingestible... ► Artikel lesen | |
| 29.10. | Gelteq Prices IPO Of 1.30 Mln Shares At $4.00/shr | 2 | RTTNews | ||
| 17.10. | Gelteq Ltd - 8-A12B, Registration of securities | - | SEC Filings | ||
| 25.09. | Gelteq Ltd - F-1/A, Registration statement for certain foreign private issuers | 3 | SEC Filings | ||
| 12.09. | Gelteq Ltd - F-1/A, Registration statement for certain foreign private issuers | 1 | SEC Filings |
14 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TONIX PHARMACEUTICALS | 0,373 | -3,19 % | Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Announces PDUFA Goal Date of August 15, 2025, for FDA Decision on U.S. Marketing Approval for TNX-102 SL for Fibromyalgia | Tonix received FDA's Day 74 Letter granting TNX-102 SL a Prescription Drug User Fee Act (PDUFA) goal date of August 15, 2025 TNX-102 SL is a non-opioid, centrally acting analgesic, granted Fast... ► Artikel lesen | |
| HARROW | 33,960 | +0,38 % | Harrow Health Aktie: Stabile Aussichten? | Der Aktienkurs des Augenheilkunde-Spezialisten Harrow Health verzeichnete am 07. Dezember einen bemerkenswerten Anstieg von 5,08 Prozent auf 39,32 USD. Die Entwicklung steht im Kontrast zum negativen... ► Artikel lesen | |
| NRX PHARMACEUTICALS | 1,620 | +3,18 % | NRx Pharmaceuticals, Inc.: NRx Pharmaceuticals (NASDAQ:NRXP) Appoints Michael Abrams as Chief Financial Officer | Industry veteran with extensive experience in key areas of focus
Interim-CFO Richard Narido to focus on HOPE Therapeutics acquisition opportunities
WILMINGTON, Del., Nov. 18, 2024... ► Artikel lesen | |
| REVIVA PHARMACEUTICALS | 1,825 | +2,53 % | Reviva Pharmaceuticals: Reviva Reports Third Quarter 2024 Financial Results and Recent Business Highlights | - 108 patients have completed 1-year of treatment in 1-year open-label extension (OLE) trial - - Vocal biomarker speech latency data from RECOVER trial reinforce brilaroxazine's improvement on negative... ► Artikel lesen | |
| OMNIAB | 3,550 | +0,57 % | OmniAb Reports Third Quarter 2024 Financial Results and Business Highlights | EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and nine months ended September 30, 2024, and provided operating and partner program... ► Artikel lesen | |
| ITERUM THERAPEUTICS | 1,825 | +4,89 % | Iterum Therapeutics PLC: Iterum Therapeutics Regains Full Nasdaq Compliance | DUBLIN and CHICAGO, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), (the Company), a company focused on delivering next generation oral and IV antibiotics to treat infections... ► Artikel lesen | |
| AQUESTIVE THERAPEUTICS | 3,590 | +1,99 % | Aquestive receives FDA Orphan Drug Exclusivity for Libervant | ||
| BRIGHT MINDS BIOSCIENCES | 36,980 | -1,73 % | PTA-News: Small- & MicroCap Investment: BB Biotech, Bright Minds, NurExone: Biotech-Konzerne sichern sich erfolgreich Privatplatzierungen | DJ PTA-News: Small- & MicroCap Investment: BB Biotech, Bright Minds, NurExone: Biotech-Konzerne sichern sich erfolgreich Privatplatzierungen
Unternehmensmitteilung für den Kapitalmarkt
Frankfurt... ► Artikel lesen | |
| VYNE THERAPEUTICS | 2,930 | -1,35 % | VYNE Therapeutics Inc.: VYNE Therapeutics Reports Positive Top-line Phase 1a MAD Data for VYN202, its Novel BD2-Selective BET Inhibitor | Promising results support VYN202's potential as a novel, once-daily oral treatment for a broad range of immune-mediated disordersConsistent with Phase 1a SAD results, VYN202 demonstrated a favorable... ► Artikel lesen | |
| PAINREFORM | 4,560 | +2,70 % | Pre-market Movers: My Size, Nvni Group, Psyence Biomedical, Humacyte, PainReform | BRASILIA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 07.55 A.M. ET).In the Green My Size, Inc. (MYSZ) is up over 372% at $6.43.
Nvni... ► Artikel lesen | |
| SKYE BIOSCIENCE | 2,510 | -1,57 % | Skye Bioscience, Inc.: Skye Bioscience Surpasses 50% Patient Enrollment in Phase 2 Obesity Study of Differentiated CB1 Inhibitor | SAN DIEGO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) ("Skye"), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health... ► Artikel lesen | |
| SUNSHINE BIOPHARMA | 3,150 | -2,78 % | Sunshine Biopharma, Inc.: Sunshine Biopharma Announces Novel Inhibitor for Sars Coronavirus | FORT LAUDERDALE, FL / ACCESSWIRE / December 9, 2024 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic... ► Artikel lesen | |
| ETON PHARMACEUTICALS | 12,890 | +1,82 % | Eton Pharmaceuticals Closes Acquisition of Increlex (mecasermin injection) | Acquisition bolsters Eton's commercial pediatric endocrinology portfolioProduct is now available through AnovoRx, a specialty pharmacy dedicated to serving patients with rare and chronic conditions... ► Artikel lesen | |
| JUPITER NEUROSCIENCES | 11,880 | +4,95 % | JUPITER NEUROSCIENCES, INC. - 10-Q, Quarterly Report | ||
| TRISALUS LIFE SCIENCES | 4,800 | +1,05 % | TriSalus Reports Q3 2024 Financial Results and Provides Business Update | DENVER--(BUSINESS WIRE)--TriSalus Life Sciences Inc., (Nasdaq: TLSI), an oncology company integrating novel delivery technology with immunotherapy to transform treatment for patients with liver... ► Artikel lesen |
Das Unternehmen GELTEQ LIMITED kann der Branche Pharma zugeordnet werden. Der aktuelle Kurs liegt bei 2,320 Euro und damit -5,31 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GELTEQ LIMITED finden Sie auf Wallstreet Online.
